Raymond James started coverage of Quince Therapeutics (QNCX) with an Outperform rating and a $72 price target. The target implies significant upside from current levels.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
